Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

v3.22.2.2
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - CAD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
CURRENT ASSETS:    
Cash and cash equivalents $ 5,861 $ 13,903
Restricted bank deposit 0 1
Trade receivables 19,441 16,711
Advances to suppliers 3,024 2,300
Other accounts receivable 6,167 14,481
Loans receivable 686 2,708
Biological assets 1,491 1,687
Inventories 26,647 29,391
Total current assets 63,317 81,182
NON-CURRENT ASSETS:    
Property, plant and equipment, net 22,671 30,268
Investments in affiliates 2,311 2,429
Advance payment for intangible assets of pharmacy 6,173 3,129
Derivative assets 8 14
Right-of-use assets, net 16,202 18,162
Deferred tax assets 679 16
Intangible assets, net 26,719 30,885
Goodwill 117,225 121,303
Total non-current assets 191,988 206,206
Total assets 255,305 287,388
CURRENT LIABILITIES:    
Trade payables 15,200 13,989
Bank Loans and credit facilities 18,002 9,502
Other accounts payable and accrued expenses 16,050 20,143
Accrued purchase consideration liabilities 2,741 6,039
Current maturities of operating lease liabilities 1,567 1,554
Total current liabilities 53,560 51,227
NON-CURRENT LIABILITIES:    
Warrants measured at fair value 319 6,022
Operating lease liabilities 16,102 17,820
Long-term loans 354 392
Employee benefit liabilities, net 180 391
Deferred tax liability, net 5,249 6,591
Total non-current liabilities 22,204 31,216
Total liabilities 75,764 82,443
EQUITY ATTRIBUTABLE TO EQUITY HOLDERS OF THE COMPANY:    
Share capital and premium 241,837 237,677
Treasury Stock (660) (660)
Translation reserve 1,004 2,614
Reserve from share-based payment transactions 14,242 12,348
Accumulated deficit (78,860) (50,743)
Total equity attributable to equity holders of the Company 177,563 201,236
Non-controlling interests 1,978 3,709
Total equity 179,541 204,945
Total liabilities and equity $ 255,305 $ 287,388